Medical Microbiology and Immunology

, Volume 200, Issue 1, pp 39–49 | Cite as

Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients

  • Stefan Reuter
  • Mark Oette
  • Frank Clemens Wilhelm
  • Bastian Beggel
  • Rolf Kaiser
  • Melanie Balduin
  • Finja Schweitzer
  • Jens Verheyen
  • Ortwin Adams
  • Thomas Lengauer
  • Gerd Fätkenheuer
  • Herbert Pfister
  • Dieter Häussinger
Original Investigation

Abstract

In HIV-infected treatment-naïve patients, we analyzed risk factors for either chronic hepatitis B (HBV) infection, occult HBV infection (OHBV) or a positive hepatitis C (HCV) serostatus. A total of 918 patients of the RESINA-cohort in Germany were included in this study. Before initiating antiretroviral therapy, clinical parameters were collected and blood samples were analyzed for antibodies against HIV, HBV and HCV, HBs antigen and viral nucleic acids for HIV and HBV. Present or past HBV infection (i.e. HBsAg and/or anti-HBc) was found in 43.4% of patients. HBsAg was detected in 4.5% (41/918) and HBV DNA in 6.1% (34/554), resulting in OHBV infection in 2.9% (16/554) of patients. OHBV infection could not be ruled out by the presence of anti-HBs (50.1%) or the absence of all HBV seromarkers (25%). A HCV-positive serostatus was associated with the IVDU transmission route, non-African ethnicity, elevated liver parameters (ASL or GGT) and low HIV viral load. Replicative HBV infection and HCV-positive serostatus both correlated with HIV resistance mutations (P = 0.001 and P = 0.028). HBV and HCV infection are frequent co-infections in HIV treatment-naive patients. These co-infections influence viral evolution, clinical parameters and serological markers. Consequently, HIV patients should routinely be tested for HBV and HCV infection before initiating HIV treatment. OHBV infection constituted almost half of all HBV infections with detectable HBV DNA. Due to a lack of risk factors indicating OHBV infection, HBV diagnosis should not only include serological markers but also the detection of HBV DNA.

Keywords

HBV HCV Co-infection Resistance mutations Occult infection 

References

  1. 1.
    Weber R, Sabin CA, Friis-Moller N et al (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166:1632–1641CrossRefPubMedGoogle Scholar
  2. 2.
    Stürmer M, Doerr HW, Gürtler L (2009) Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med Microbiol Immunol 198(3):147–155Google Scholar
  3. 3.
    Rockstroh JK (2006) Influence of viral hepatitis on HIV infection. J Hepatol 44:S25–S27CrossRefPubMedGoogle Scholar
  4. 4.
    Hofer M, Joller-Jemelka HI, Grob PJ et al (1998) Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 17:6–13CrossRefPubMedGoogle Scholar
  5. 5.
    Nunez M, Rios P, Perez-Olmeda M et al (2002) Lack of ‘occult’ hepatitis B virus infection in HIV-infected patients. AIDS 16:2099–2101CrossRefPubMedGoogle Scholar
  6. 6.
    Jilg W, Sieger E, Zachoval R et al (1995) Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 23:14–20CrossRefPubMedGoogle Scholar
  7. 7.
    Thio CL, Netski DM, Myung J et al (2004) Changes in hepatitis B virus DNA levels with acute HIV infection. Clin Infect Dis 38:1024–1029CrossRefPubMedGoogle Scholar
  8. 8.
    Yamamoto K, Horikita M, Tsuda F et al (1994) Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 68:2671–2676PubMedGoogle Scholar
  9. 9.
    Jeantet D, Chemin I, Mandrand B et al (2004) Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 73:508–515CrossRefPubMedGoogle Scholar
  10. 10.
    Vivekanandan P, Kannangai R, Ray SC et al (2008) Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 46:1227–1236CrossRefPubMedGoogle Scholar
  11. 11.
    Filippini P, Coppola N, Pisapia R et al (2007) Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. J Med Virol 79:1679–1685CrossRefPubMedGoogle Scholar
  12. 12.
    Raimondo G, Pollicino T, Romano L et al. (2010) A 2010 update on occult hepatitis B infection. Pathol Biol (Paris)Google Scholar
  13. 13.
    Neau D, Winnock M, Jouvencel AC et al (2005) Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002–2003. Clin Infect Dis 40:750–753CrossRefPubMedGoogle Scholar
  14. 14.
    Shire NJ, Rouster SD, Stanford SD et al (2007) The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 44:309–314CrossRefPubMedGoogle Scholar
  15. 15.
    Lo RV III, Frank I, Gross R et al (2007) Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44:315–320CrossRefGoogle Scholar
  16. 16.
    Dorrucci M, Valdarchi C, Suligoi B et al (2004) The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS 18:2313–2318CrossRefPubMedGoogle Scholar
  17. 17.
    Klein MB, Lalonde RG, Suissa S (2003) The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33:365–372PubMedGoogle Scholar
  18. 18.
    Sagir A, Oette M, Kaiser R et al (2007) Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60:843–848CrossRefPubMedGoogle Scholar
  19. 19.
    Allen MI, Deslauriers M, Andrews CW et al (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670–1677CrossRefPubMedGoogle Scholar
  20. 20.
    Oette M, Kaiser R, Daumer M et al (2004) Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 9:273–278PubMedGoogle Scholar
  21. 21.
    Hadler SC, Judson FN, O’Malley PM et al (1991) Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 163:454–459PubMedGoogle Scholar
  22. 22.
    Puoti M, Airoldi M, Bruno R et al (2002) Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 4:27–35PubMedGoogle Scholar
  23. 23.
    Santos EA, Yoshida CF, Rolla VC et al (2003) Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 22:92–98PubMedGoogle Scholar
  24. 24.
    Sucupira MV, Mello FC, Santos EA et al (2006) Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz 101:655–660CrossRefPubMedGoogle Scholar
  25. 25.
    Gandhi RT, Wurcel A, McGovern B et al (2003) Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 34:439–441CrossRefPubMedGoogle Scholar
  26. 26.
    Neau D, Winnock M, Galperine T et al (2004) Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 5:171–173CrossRefPubMedGoogle Scholar
  27. 27.
    Filippini P, Coppola N, Pisapia R et al (2006) Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20:1253–1260CrossRefPubMedGoogle Scholar
  28. 28.
    Wagner AA, Denis F, Weinbreck P et al (2004) Serological pattern ‘anti-hepatitis B core alone’ in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 18:569–571CrossRefPubMedGoogle Scholar
  29. 29.
    Azadmanesh K, Mohraz M, Aghakhani A et al (2008) Occult hepatitis B virus infection in HIV-infected patients with isolated hepatitis B core antibody. Intervirology 51:270–274CrossRefPubMedGoogle Scholar
  30. 30.
    Pogany K, Zaaijer HL, Prins JM et al (2005) Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses 21:922–926CrossRefPubMedGoogle Scholar
  31. 31.
    Rai RR, Mathur A, Mathur D et al (2007) Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission. Trop Gastroenterol 28:19–23PubMedGoogle Scholar
  32. 32.
    Sheng WH, Kao JH, Chen PJ et al (2007) Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 45:1221–1229CrossRefPubMedGoogle Scholar
  33. 33.
    Shire NJ, Rouster SD, Rajicic N et al (2004) Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 36:869–875CrossRefPubMedGoogle Scholar
  34. 34.
    Araujo NM, Branco-Vieira M, Silva AC et al (2008) Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Hepatol Res 38:1194–1203PubMedGoogle Scholar
  35. 35.
    Nebbia G, Garcia-Diaz A, Ayliffe U et al (2007) Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 79:1464–1471CrossRefPubMedGoogle Scholar
  36. 36.
    French AL, Operskalski E, Peters M et al (2007) Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 195:1437–1442CrossRefPubMedGoogle Scholar
  37. 37.
    Piroth L, Binquet C, Vergne M et al (2002) The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 36:681–686CrossRefPubMedGoogle Scholar
  38. 38.
    Greub G, Ledergerber B, Battegay M et al (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356:1800–1805CrossRefPubMedGoogle Scholar
  39. 39.
    Morsica G, Bagaglio S, Ghezzi S et al (2007) Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression. J Clin Virol 39:82–86CrossRefPubMedGoogle Scholar
  40. 40.
    Zhang X, Xu J, Peng H et al (2008) HCV coinfection associated with slower disease progression in HIV-infected former plasma donors naive to ART. PLoS One 3:e3992CrossRefPubMedGoogle Scholar
  41. 41.
    Ramos B, Nunez M, Martin-Carbonero L et al (2007) Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 44:557–561CrossRefPubMedGoogle Scholar
  42. 42.
    Lindh M, Andersson AS, Gusdal A (1997) Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus–large-scale analysis using a new genotyping method. J Infect Dis 175:1285–1293CrossRefPubMedGoogle Scholar
  43. 43.
    Erhardt A, Blondin D, Hauck K et al (2005) Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 54:1009–1013CrossRefPubMedGoogle Scholar
  44. 44.
    Laguno M, Larrousse M, Blanco JL et al (2008) Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients. AIDS Res Hum Retroviruses 24:547–553CrossRefPubMedGoogle Scholar
  45. 45.
    Morsica G, Ancarani F, Bagaglio S et al (2009) Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features. Infection 37:445–449CrossRefPubMedGoogle Scholar
  46. 46.
    Palacios R, Mata R, Hidalgo A et al (2008) Very low prevalence and no clinical significance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti-HBc seropositivity: the BHOI study. HIV Clin Trials 9:337–340CrossRefPubMedGoogle Scholar
  47. 47.
    Piroth L, Lafon ME, Binquet C et al (2008) Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis 40:835–839CrossRefPubMedGoogle Scholar
  48. 48.
    Quarleri J, Moretti F, Bouzas MB et al (2007) Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses 23:525–531CrossRefPubMedGoogle Scholar
  49. 49.
    Ramia S, Mokhbat J, Ramlawi F et al (2008) Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen. Int J STD AIDS 19:197–199CrossRefPubMedGoogle Scholar
  50. 50.
    Rodriguez-Torres M, Gonzalez-Garcia J, Brau N et al (2007) Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol 79:694–700CrossRefPubMedGoogle Scholar
  51. 51.
    Taylor L, Gholam P, Delong A et al (2008) Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS. In: 17th International AIDS conference. Mexico City, MexicoGoogle Scholar
  52. 52.
    Torres-Baranda R, Bastidas-Ramirez BE, Maldonado-Gonzalez M et al (2006) Occult hepatitis B in Mexican patients with HIV, an analysis using nested polymerase chain reaction. Ann Hepatol 5:34–40PubMedGoogle Scholar
  53. 53.
    Tsui JI, French AL, Seaberg EC et al (2007) Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis 45:736–740CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Stefan Reuter
    • 1
  • Mark Oette
    • 2
  • Frank Clemens Wilhelm
    • 3
  • Bastian Beggel
    • 4
  • Rolf Kaiser
    • 3
  • Melanie Balduin
    • 3
  • Finja Schweitzer
    • 3
  • Jens Verheyen
    • 3
  • Ortwin Adams
    • 5
  • Thomas Lengauer
    • 4
  • Gerd Fätkenheuer
    • 6
  • Herbert Pfister
    • 3
  • Dieter Häussinger
    • 1
  1. 1.Clinic of Gastroenterology, Hepatology and Infectious DiseasesUniversity HospitalDuesseldorfGermany
  2. 2.Clinic of General Medicine, Gastroenterology and Infectious DiseasesAugustinerinnen HospitalCologneGermany
  3. 3.Institute of VirologyUniversity of CologneCologneGermany
  4. 4.Max Planck Institute for Informatics, Computational Biology and Applied AlgorithmicsSaarbrueckenGermany
  5. 5.Institute of VirologyUniversity Hospital of DüsseldorfDüsseldorfGermany
  6. 6.Department of Internal Medicine IUniversity Hospital of CologneCologneGermany

Personalised recommendations